EC approves B-MS/Gilead's Atripla
The European Commission has approved US drugmakers Bristol-Myers Squibb and Gilead Sciences' Atripla (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg), the first-ever one-pill-a-day regimen for the treatment of HIV infection, for use in the 27 member states of the European Union. The drug will be made available first in the UK and Germany.
According to the firms, HIV/AIDS remains a significant health risk for Europeans. An estimated 181,000 new HIV infections occurred in Europe in 2007 and the UNAIDS estimates that 2.4 million people are now living with HIV in the European region. Of these, 30% are estimated to be unaware of their infection, and only 14% are believed to be taking anti-HIV medicines. Atripla was approved in the USA in 2006.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze